Top Markets
#1 Cortex Cortex +173.60%
#2 GEKKO GEKKO +51.79%
#3 Audiera Audiera +20.32%
#4 Helium Helium +19.19%
#5 ADO Protocol ADO Protocol +17.84%
#6 Pons Pons +15.28%
#7 TENDIES TENDIES +13.31%
#8 o1.exchange o1.exchange +13.30%
#9 Ontology Gas Ontology Gas +13.20%
#10 aelf aelf +9.81%
Coin of the day
Cortex Cortex
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Rang in Aktien #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Aktienkurs
$14.07
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$1.18B
Veränderung (1 Tag)
-4.41%
Veränderung (1 Jahr)
145.13%
Land
US
Handel Corvus Pharmaceuticals, Inc. (CRVS)

Kategorie

Healthcare
Kursverlauf für Corvus Pharmaceuticals, Inc. (CRVS)
Höchster Schlusskurs: $14.55 am 2026-08-01

Niedrigster Schlusskurs: $14.35 am 2016-03-01
Kursverlauf der Aktie von Corvus Pharmaceuticals, Inc. von 2016 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 52.04%
2025 20.69%
2024 304.94%
2023 86.02%
2022 -68.55%
2021 -28.60%
2020 -6.17%
2019 -13.67%
2018 -53.58%
2017 -32.68%
2016 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH